Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib and Cemiplimab in Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT05882734Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Sep 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of tuvusertib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by EMD Serono. Primary endpoints: Confirmed Overall Response and Number of Participants With Adverse Events and Treatment-related AEs. Started Sep 2023; status: completed.
02
Drugs
tuvusertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05882734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882734.